Profil
Dr. Greg F.
Walker is a Manager-Research & Development at Haemostatix Ltd.
Dr. Walker was previously employed as a Principal by University of Munich and a Principal by University of Vienna.
He received his doctorate degree from the University of Otago.
Ehemalige bekannte Positionen von Greg F. Walker
| Unternehmen | Position | Ende |
|---|---|---|
| Ludwig-Maximilians-Universität München | Corporate Officer/Principal | 01.01.2006 |
| University of Vienna | Corporate Officer/Principal | 01.01.2002 |
Haemostatix Ltd.
 Haemostatix Ltd. Pharmaceuticals: MajorHealth Technology Haemostatix Ltd. designs and develops solutions for haemostasis and thrombosis. Its products include Rapid and effective haemostatic action which is new class of topical coagulant or haemostat that is applied directly to a wound during surgery to control bleeding, and ready-to-use formulations, blood-free ingredients and a new class with a unique mode of action. The company was founded by Sarah Middleton and Alison Goodall in 2003 and is headquartered in Nottingham, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Greg F. Walker
| University of Otago | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Haemostatix Ltd.
Haemostatix Ltd. Pharmaceuticals: MajorHealth Technology Haemostatix Ltd. designs and develops solutions for haemostasis and thrombosis. Its products include Rapid and effective haemostatic action which is new class of topical coagulant or haemostat that is applied directly to a wound during surgery to control bleeding, and ready-to-use formulations, blood-free ingredients and a new class with a unique mode of action. The company was founded by Sarah Middleton and Alison Goodall in 2003 and is headquartered in Nottingham, the United Kingdom. | Health Technology |
